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Accumulation of intracellular tau fibrils has been the
focus of research on the mechanisms of neurode-
generation in Alzheimer’s disease (AD) and related
tauopathies. Here, we have developed a class of
tau ligands, phenyl/pyridinyl-butadienyl-benzothia-
zoles/benzothiazoliums (PBBs), for visualizing
diverse tau inclusions in brains of living patients
with AD or non-AD tauopathies and animal models
of these disorders. In vivo optical and positron emis-
sion tomographic (PET) imaging of a transgenic
mouse model demonstrated sensitive detection
of tau inclusions by PBBs. A pyridinated PBB,
[11C]PBB3, was next applied in a clinical PET study,
and its robust signal in the AD hippocampus wherein
tau pathology is enriched contrasted strikingly with
that of a senile plaque radioligand, [11C]Pittsburgh
Compound-B ([11C]PIB). [11C]PBB3-PET data were
also consistent with the spreading of tau pathology
with AD progression. Furthermore, increased
[11C]PBB3 signals were found in a corticobasal syn-
drome patient negative for [11C]PIB-PET.
INTRODUCTION
Hallmark pathologies of Alzheimer’s disease (AD) are extracel-
lular senile plaques consisting of aggregated amyloid b peptide1094 Neuron 79, 1094–1108, September 18, 2013 ª2013 Elsevier Inc(Ab) and intraneuronal neurofibrillary tangles (NFTs) composed
of pathological tau fibrils, while similar tau lesions in neurons
and glia are also characteristic of other neurodegenerative disor-
ders, such as progressive supranuclear palsy (PSP) and cortico-
basal degeneration (CBD), that are collectively referred to as
tauopathies (Ballatore et al., 2007). The discovery of tau gene
mutations in a familial form of tauopathy, known as frontotem-
poral dementia and parkinsonism linked to chromosome 17
(FTDP-17), and subsequent studies of transgenic (Tg) mice
expressing human tau with or without these mutations, clearly
implicate pathological tau in mechanisms of neurodegeneration
in AD and related tauopathies (Ballatore et al., 2007). Thus, there
is an urgent need for tau imaging techniques to complement Ab
amyloid imaging methods that now are widely used.
In vivo imaging modalities, as exemplified by positron emis-
sion tomography (PET) (Klunk et al., 2004; Small et al., 2006;
Kudo et al., 2007; Maeda et al., 2007), optical scanning (Bacskai
et al., 2003; Hintersteiner et al., 2005), and magnetic resonance
imaging (MRI) (Higuchi et al., 2005), have enabled visualization of
Ab deposits in humans with AD and/or AD mouse models, and
there has been a growing expectation that low-molecular-weight
ligands for b-pleated sheet structures will also serve as molecu-
lar probes for tau amyloids. Although the majority of plaque-
imaging agents used for clinical PET studies do not bind to tau
lesions (Klunk et al., 2003), at least one radiolabeled b sheet
ligand, [18F]FDDNP, enables PET imaging of AD NFTs (Small
et al., 2006). However, a relatively low contrast of in vitro autora-
diographic and in vivo PET signals for [18F]FDDNP putatively re-
flecting tau lesions does not allow a simple visual inspection of
images for the assessment of tau pathologies in living subjects.
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radioligands with higher affinity for tau fibrils and/or less nonspe-
cific binding to tissues are urgently needed to complement
high-contrast senile plaque imaging agents, including widely
studied [11C]Pittsburgh Compound-B ([11C]PIB) (Klunk et al.,
2004) and United States Food and Drug Administration-
approved [18F]florbetapir (Yang et al., 2012). In addition,
[18F]FDDNP and several other candidate tau probes do not
bind to tau inclusions in non-AD tauopathy brains without plaque
deposition (Okamura et al., 2005) and therefore can be clinically
characterized only in AD patients with comingled Ab and tau
amyloids. Hence, compounds that detect diverse tau aggre-
gates, including tau inclusions in non-AD neurodegenerative dis-
eases and tau Tg models, could be used to interrogate in vivo
interactions between exogenous ligands and tau pathologies.
Here, we found that the lipophilicity of b sheet ligands is asso-
ciated with their selectivity for tau versus Ab fibrils and that the
core dimensions of these chemicals are major determinants of
their reactivity with a broad spectrum of tau aggregates in
diverse tauopathies and mouse models of tau pathology. Build-
ing on these observations, we developed a series of fluorescent
compounds capable of detecting diverse tau lesions using
optical and PET imaging in living Tg mouse models of tauopa-
thies. Finally, we identified a radiotracer that produced the
highest contrast for tau inclusions in animal PET and used it in
exploratory in vivo imaging studies of AD patients, providing
clear demonstration of signal intensification in tau-rich regions,
in sharp distinction to [11C]PIB-PET data reflecting plaque
deposition.
RESULTS
Identification of PBBs as Ligands for Diverse Tau
Inclusions in Human Tauopathies
We screened an array of fluorescent chemicals capable of bind-
ing to b sheet conformations (see the Compounds subsection in
the Experimental Procedures). Fluorescence labeling with these
compounds were examined in sections of AD brains bearing Ab
and tau amyloids (Figures 1A and 2A) and non-AD tauopathy
brains characterized by tau inclusions and few or no Ab plaques
(Figure 2). Amyloid PET tracers currently used for human PET
studies, PIB (Klunk et al., 2004), and BF-227 (Kudo et al.,
2007), tightly bound to senile plaques, while they only weakly re-
acted with AD NFTs (Figures 1A; Figure S1 available online). PET
probes reported to selectively label tau aggregates, BF-158
(Okamura et al., 2005) and THK523 (Fodero-Tavoletti et al.,
2011), detected AD NFTs (Figures 2A and S1) but microscopi-
cally detectable fluorescence signals produced by FDDNP,
which are presumed to bind to both Ab and tau fibrils (Small
et al., 2006), were consistent with dense cores of classic plaques
and distinct from tau lesions (Figures 2A and S1). None of
the above-mentioned PET ligands were reactive with tau
inclusions in non-AD tauopathies, such as Pick bodies in Pick’s
disease (Figures 2A and S1) and neuronal and glial fibrillary
lesions in PSP and CBD (data not shown). By contrast, these
pathologies were intensely labeled with a widely used amyloid
dye, thioflavin-S, and a derivative of another classic amyloid
dye Congo red, (E,E)-1-fluoro-2,5-bis(3-hydroxycarbonyl-4-Neuhydroxy)styrylbenzene (FSB) (Higuchi et al., 2005; Maeda
et al., 2007) (Figures 1, 2A, and S1), although these chemicals
may not undergo efficient transfer through the blood-brain
barrier (BBB) (Zhuang et al., 2001). Because compounds pos-
sessing a p-electron-conjugated backbone longer than 13A˚ ex-
hibited affinities for pathological inclusions in a broad range of
tauopathies, we examined binding of additional chemicals with
a variety of structural dimensions to tau aggregates and found
that affinity for non-AD tau inclusions could be attributed to a
core structure with a specific extent ranging from 13 to 19 A˚ (Fig-
ure S1). Based on this view and the known fact that chemicals
with a flat and slender backbone could pass through and attach
to channel-like accesses in b-pleated sheets (Krebs et al.,
2005), we developed a class of compounds, phenyl/pyridinyl-
butadienyl-benzothiazoles/benzothiazoliums (PBBs), by stretch-
ing the core structure of a prototypical fluorescent amyloid dye,
thioflavin-T, with two C = C double bond inserts between aniline
(or aminopyridine) and benzothiazole (or benzothiazolium)
groups (Figure 1B).
All PBB compounds intensely labeled NFTs, neuropil threads,
and plaque neurites in AD brains (Figure 1C). Interestingly, the
affinity of these PBBs for Ab plaques lacking dense cores was
positively correlated with their lipophilicity (Figure 1C), and
thereby three potential probes with relatively low logP (log
of the octanol/water partition coefficient) values, including
PBB3, 2-[4-(4-methylaminophenyl)-1,3-butadienyl]-benzothia-
zol-5,6-diol (PBB4) and PBB5 (structurally identical to Styryl 7,
CAS registry number 114720-33-1), appeared suitable for
visualizing tau pathologies in living organisms with reasonable
selectivity. High-affinity of PBBs for tau lesions was further
demonstrated by fluorometric analyses using Ab and tau fila-
ments assembled in a test tube (Table S1; experimental proce-
dures are given in the Supplemental Experimental Procedures),
but the most and least lipophilic PBBmembers displayed similar
selectivity for in vitro tau versus Ab pathologies, implying a
methodological limitation in screening chemicals for tau-
selective ligands based on binding to synthetic peptides and
recombinant proteins. PBBs and FSB were also shown to label
tau inclusions in non-AD tauopathies, such as Pick’s disease
(Figures 2A and S1), PSP, and CBD (Figure 2B), all of which
were immunodetected by an antibody specific for phosphory-
lated tau proteins (AT8).
In Vitro and Ex Vivo Fluorescence Imaging of Tau
Lesions in Tau Tg Mice by PBBs
To obtain in vivo evidence of direct interaction between PBBs
and tau lesions, we employed Tg mice expressing a single
human four-repeat tau isoform with the P301S FTDP-17 muta-
tion (PS19 line, see Figure S2 for neuropathological features of
this Tg strain) (Yoshiyama et al., 2007). Similar to the findings
in non-AD tauopathy brains, NFT-like inclusions in the brain
stem and spinal cord of PS19 mice were clearly recognized by
PBBs (Figures 3A and S1). We then performed ex vivo fluores-
cence labeling of tau lesions in PS19 mice with intravenously
administered PBBs. Brains and spinal cords were removed
60 min after tracer injection, and fluorescence microscopy re-
vealed an intense accumulation of these compounds in fibrillary
tau inclusions abundantly seen throughout the sections byron 79, 1094–1108, September 18, 2013 ª2013 Elsevier Inc. 1095
Figure 1. Design and Characterization of PBB Compounds as Potential Imaging Agents for Tauopathies
(A) Confocal fluorescence images of frontal cortex sections from an AD patient. Following fluorescence labeling (pseudocolors are converted to green) with PIB
(top row) and FSB (middle row), the samples were immunostained with an antibody against AbN3(pE) (red in the right column). PIB intensely labeled Ab plaques
(white arrowheads) but did not clearly label NFTs (arrows). By contrast, NFTs and neuropil threads were intensely labeled by FSB, whereas the staining of diffuse
plaques was negligible. A section was also doubly immunolabeled (bottom row) with AT8 (green) and anti-AbN3(pE) antibodies (red in the right panel), to
demonstrate the abundance of tau and Ab amyloids in this area. Yellow arrowheads indicate tau-positive dystrophic neurites associated with senile plaques.
(B) Structures of PBBs. Neutral benzothiazoles (PBB1-4) are newly synthesized chemicals, and a charged benzothiazolium, PBB5, is identical to a commercially
available near-infrared laser dye.
(C) Confocal fluorescence images of PBBs (pseudocolors are converted to green) and AbN3(pE) (red in the right column) staining in sections adjacent to those
displayed in (A). The intensity of plaque staining (arrowheads) relative to that of NFTs (arrows) was positively associated with the lipophilicity of PBBs. As
compared with PBB1 (top row) staining, labeling of diffuse plaques with PBB3 (middle row) was substantially attenuated. PBB5was nearly unreactive with diffuse
plaques (bottom row), and subsequent double immunofluorescence staining of the same section (bottom row in C) illustrated good agreement of PBB5 labeling
with the distribution of AT8-positive NFTs.
Scale bar, 50 mm (A and C). See also Figure S1 and Table S1.
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hand, no overt in vitro (Figure 3A) or ex vivo (data not shown) fluo-
rescence of these ligands was noted in the corresponding
regions of non-Tg wild-type (WT) mice. Consistent with these
observations, two-photon laser scanning fluorescence micro-
scopy of ex vivo samples demonstrated somatic and neuritic
staining of a subset of tangle-bearing neurons with intravenously
injected 2-[4-(4-methylaminophenyl)-1,3-butadienyl]-benzothia-1096 Neuron 79, 1094–1108, September 18, 2013 ª2013 Elsevier Inczol-6-ol (PBB2) and PBB4 in unsliced spinal cord blocks from
PS19 mice (Figure 3B).
In Vivo Macroscopic and Mesoscopic Optical Detection
of Fibrillar Tau Pathologies in a Mouse Model Using
PBB5
We next characterized PBBs with the use of in vivo fluorescence
imaging modalities, which permitted a quick assessment of.
Figure 2. Binding of Tau Ligands to Tau Lesions in AD and Non-AD Tauopathy Brains
(A) Double fluorescence staining of AD NFTs and Pick bodies (PBs) in Pick’s disease with PBBs, other tau ligands, and anti-phospho-tau antibody (AT8). FSB and
PBBs sensitively captured ADNFTs and PBs. ADNFTswere labeled with THK523. Meanwhile, PBswere not visualized by these compounds. NFTs and PBswere
barely recognizable by using FDDNP.
(B) Double fluorescence staining of neuronal tau inclusions (arrows) in PSP andCBD and putative astrocytic plaques (arrowheads) in CBD. A substantial portion of
tau fibrils in neurons were captured by PBB3 and PBB5, but a much smaller subset of phosphorylated tau aggregates in astrocytic plaques were labeled with
these compounds.
Scale bar, 20 mm (A and B). See also Figures S2 and S3.
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PBB5 is fluorescent, with peak excitation and emission wave-
lengths in a near-infrared range (Table S1), this compound is
applicable to in vivo optical imaging of tau deposits in laboratory
animals. To examine this possibility, fluorescence images were
obtained from living mice over a time course following intrave-
nous PBB5 injections using a small animal-dedicated system
permitting the intravital observation of fluorescence signals at
magnifications varying between macroscopic and microscopic
levels. Tail vein administration of PBB5 in PS19 mice revealed
strong fluorescence relative to non-Tg WT mice in the central
nervous system (CNS) above the slit between the base of the
skull and first vertebra, through the skin and connective tissues
overlaying the cisterna magna (Figures S3A–S3D), suggesting
a concentration of this tracer in the PS19 spinal cord. In line
with this in vivo observation, the hindbrain and spinal cord of
PS19 mice, which were dissected out at 2 hr after the injection
of PBB5, exhibited increased retention of this compound
compared to non-Tg WT mice (Figures S3E–S3G).
In vivo optical imaging of tau Tg mice was subsequently per-
formed using a device equipped with a pulsed diode laser and
a photomultiplier tube to detect deep signals through the skull.
Elevated levels of fluorescence intensity were found in homoge-
nized brain stem samples collected fromPS19mice at 20 hr after
the intravenous tracer administration (Figure S4A), indicating a
long-lasting in vivo binding of PBB5 to tau fibrils. To supportNeuthe ex vivo evidence, fluorescence intensity was noninvasively
analyzed in living PS19 and non-Tg WT mice treated with
PBB5. The mice, with their heads shaved in advance, were pre-
scanned, and autofluorescence signals were detected at a rela-
tively high level in an area corresponding to the frontal forebrain.
Using these baseline signals as landmarks, regions of interest
(ROIs) were defined in the frontal cortex, brain stem, and spinal
cord (Figure 4A). The near-infrared fluorescence was notably
increased immediately after the intravenous injection of PBB5
(Figure S4C), and the fluorescence in the brain stem and spinal
cord ROIs of PS19 mice much exceeded that in WT mice at
30 min (Figure 4B). Fluorescence intensity in the frontal cortex
ROI, normalized on the basis of integration time and laser power,
was lower in PS19mice than inWTmice over 120min after tracer
injection (Figure S4B), which may reflect impaired CNS delivery
of the tracer in Tg mice due to degenerative changes (see Fig-
ures S4C–S4L for details), and thereafter this became almost
equivalent between the two genotypes (Figure S4B). Meanwhile,
persistent retention of the signals in the brain stem and spinal
cord ROIs of PS19 mice was observed beyond 240 min (Figures
4B and S4B). A more quantitative index comparable among
different mice was determined by calculating the target-to-
frontal-cortex ratio of fluorescence intensity and was shown to
increase over time particularly in PS19 mice (Figures 4C and
4D). This ratio was significantly greater in PS19 mice than in
WT mice at 240 min (Figure 4E), beyond which the differenceron 79, 1094–1108, September 18, 2013 ª2013 Elsevier Inc. 1097
Figure 3. In Vitro and Ex Vivo Labeling of NFTs in PS19 Mice with PBB Compounds
(A) Double fluorescence staining of intraneuronal tau aggregates in postmortem brain stem slices of a 12-month-old PS19 mouse with PBB, other amyloid
ligands, and anti-phospho-tau antibody (AT8).
(B) Binding of intravenously administered PBBs (0.1 mg/kg PBB5 and 1 mg/kg PBB1 and PBB3) to NFTs in PS19 mice at 10–12 months of age. The tissues were
sampled at 60 min after tracer administration. The brain stem (top row) and spinal cord (second and third rows from the top) sections abundantly contained
neurons showing strong fluorescence (left), and subsequent staining with FSB or AT8 (right) indicated that these cells were laden with tau amyloid fibrils (right).
Putative intraneuronal tau inclusions in unsectioned spinal cords (arrowheads in the bottom row) removed from PS19mice at 60min after intravenous injection of
PBB2 and PBB4 were also clearly visible by using a two-photon (2P) fluorescence microscopic system. Arrow in the bottom row indicates a cluster of auto-
fluorescence signals from blood cells.
Scale bars, 25 mm (A), 30 mm (top to third rows in B), and 20 mm (bottom row in B).
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4C and 4D). The intensity ratio of the spinal cord ROI to the frontal
cortex in PS19 mice at 240 min was also significantly correlated
with the abundance of NFTs stained with FSB (Figure 4F), but
such correlations were not statistically significant in the brain
stem (Figure 4F), implying limitations of the intensitometry in
some brain regions below the cerebellum and fourth ventricle.
Intravital Imaging of Individual Tau Inclusions by PBB3
and Two-Photon Laser Scanning Fluorescence
Microscopy
Two-photon excitation microscopy, which enables optical
sectioning, potentially up to 1 mm deep, in living tissues, could
be utilized to visually demonstrate transfer of a fluorescent probe
from the plasma compartment into the cytoplasm of CNS neu-
rons and binding of the probe to intraneuronal tau inclusions.
We therefore captured fluorescence signals from intravenously
administered PBB3 by in vivo two-photon laser scanning micro-
scopic imaging of the spinal cord of laminectomized PS19 mice.
Within 3 s of PBB3 injection, green fluorescence signals
emerged in blood vessels prelabeled with red with intraperito-
neal treatment using sulforhodamine 101 and subsequently
diffused from the vasculatures to the spinal cord parenchyma1098 Neuron 79, 1094–1108, September 18, 2013 ª2013 Elsevier Incover the next few minutes (Figures 5A–5F). These diffuse signals
declined thereafter due to the clearance of PBB3 from the tissue,
whereas intense labeling of putative tau inclusions with green
fluorescence appeared in a subpopulation of large cells morpho-
logically identified as neurons at 3–5 min after PBB3 injection
(Figures 5G and 5H). These intracellular PBB3 fluorescent sig-
nals were not found in the spinal cord of WT mice (Figure 5I).
As the BBB of the brain and spinal cord are presumed to be iden-
tical, the two-photon microscopic data obtained here provide
compelling evidence that PBB3 rapidly transits the BBB and
neuronal plasma membranes, where it binds to intraneuronal
tau inclusions. Accumulation of injected PBB3 in AT8-positive,
NFT-like lesions of Tg mice was postmortemly confirmed by
ex vivo microscopy (Figures 5J and 5K).
Autoradiographic and PET Imaging of Tau Lesions in
PS19 Mice by Radiolabeled PBBs
We investigated the kinetic properties of PBBs by high-perfor-
mance liquid chromatography (HPLC) analyses of plasma and
brain samples collected from non-TgWTmice treated with these
ligands. Following intravenous administration, PBB5 was rapidly
converted into a major metabolite, which at 5 min was found at
high levels in both plasma and brain extracts. Subsequent liquid.
Figure 4. Noninvasive Near-Infrared Imaging of Tau Pathology in Living Tau Tg Mice Using Pulsed Laser Optics and PBB5
(A) Baseline autofluorescence signals (middle) are overlaid on the visible background image of a shaven non-TgWTmouse head (left). Ellipsoidal ROIs are defined
above the frontal cortex (FC), brain stem (BS), and cervical spinal cord (SC) guided by a relatively intense emission from the FC region (right).
(B) Fluorescence intensity maps in 12-month-oldWT (top) and PS19 (Tg; bottom) mice before and at 30 and 240min after the intravenous administration of PBB5
(0.1 mg/kg). The intensity maps (A and B) are normalized by the FC ROI value at 30 min after tracer injection. Long-lasting retention of the tracer was noted in the
BS and SC ROIs of the Tg mouse.
(C and D) Target-to-FC ratios of fluorescence intensity in the BS (C) and SC (D) ROIs over the image acquisition time in the WT (open circles; n = 7) and PS19
(closed circles; n = 7) mice. There were significant main effects of time, region, and genotype in two-way, repeated-measures ANOVA (time, F(11, 132) = 17.6, p <
0.001; region, F(1, 12) = 29.9, p < 0.001; genotype, F(1, 12) = 23.6, p < 0.001).
(E) Target-to-FC ratios in the BS and SC ROIs of the WT (open columns) and tau Tg (closed columns) mice at 240 min after tracer injection. *p < 0.05; **p < 0.01;
two-way repeated-measures ANOVA with Bonferroni’s post hoc analysis.
(F) Scatterplots of target-to-FC ratios at 240min versus the number of FSB-positive NFTs per unit area of postmortem 20 mm tissue slices in BS (blue symbols) and
SC (red symbols) ROIs of tau Tg mice. Solid lines represent regressions; p values were determined by t test. Vertical bars in the graphs represent SEs.
See also Figures S3 and S4.
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gested that the major metabolite was likely a reduced, electri-
cally neutralized derivative of PBB5 (Figures S5A and S5B).
Besides transventricular uptake of unmetabolized PBB5 as
implied above, this uncharged form incapable of emitting near-
infrared light could readily penetrate the BBB, as well as cell
membranes, and thereafter could be reoxidized into its original
form, thereby enabling it to bind to tau fibrils, particularly at sites
exposed to oxidative stress in pathological conditions. In addi-
tion, PBB4 was promptly converted to metabolites capable of
entering the brain. Finally, studies of PBB2 and PBB3 showed
that they exhibited reasonable biostability and sufficient entry
into and clearance from the brain. Indeed, HPLC assays demon-
strated that fractions of unmetabolized PBB2 and PBB3 in
mouse plasma were 23.5% and 16.3%, respectively, at 3 min
after intravenous administration and were 4.6% and 2.8%,
respectively, at 30 min. There were also no metabolites of
PBB2 and PBB3 detectable in the mouse brain at 3 and 30 min.
We then radiolabeled PBB2 and PBB3 with 11C to conduct
autoradiographic and PET assays using PS19mice. In vitro auto-
radiography using frozen tissue sections showed binding of
these radioligands to the brain stem of PS19mice and neocortex
of AD patients (Figure 6A). As expected from their lipophilicities,Neu[11C]PBB3 yielded high-contrast signals with less nonspecific
labeling of myelin-rich white matter than did [11C]PBB2, and
the accumulation of [11C]PBB3 in pathological regions was
nearly completely abolished by the addition of nonradioactive
compounds. Similarly, ex vivo autoradiographic studies demon-
strated that intravenously administered [11C]PBB3 selectively
labeled the brain stem and spinal cord of PS19 mice harboring
neuronal tau inclusions, whereas tau-associated [11C]PBB2
radiosignals were less overt because of a considerable level of
nonspecific background (Figure 6B; Figures S6C–S6F). Finally,
in vivo visualization of tau lesions in PS19 mouse brains was
enabled by a microPET system using these two tracers (Figures
6C, S6A, and S6B). Following intravenous injection, [11C]PBB3
rapidly crossed the BBB and unbound and nonspecifically
bound tracers were promptly washed out from the brain with a
half-life of 10 min (left panel in Figure 6E). The retention of
[11C]PBB3 signals in the brain stem of 12-month-old PS19
mice lasted over the imaging time (90 min), producing a pro-
nounced difference from that in age-matched non-Tg WT mice
(left panel in Figure 6E). By selecting the striatum as a reference
region lacking tau deposits, the target-to-reference ratio was
estimated for the brain stem,with the value in PS19mice peaking
at around 70 min, contrasting with its continuous decrease overron 79, 1094–1108, September 18, 2013 ª2013 Elsevier Inc. 1099
Figure 5. Real-Time Two-Photon Laser
Scanning Images of PBB3 Diffusing from
Vessels, Binding to Intraneuronal Tau Inclu-
sions, and Clearing from Spinal Cord
(A–H) A maximum projection of fluorescence in a
3D volume of the spinal cord of a living PS19
mouse at 12 months of age before (A) and at
various time points after (B–H) intravenous
administration of PBB3 (1 mg/kg). Blood vessels
were labeled with sulforhodamine 101 (red) intra-
peritoneally injected at 15 min before PBB3
administration. Green fluorescence indicates a
rapid transfer of PBB3 from the plasma to tissue
parenchyma (B–E) and subsequent washout
from the tissue (F). Background PBB3 signals
were further attenuated beyond 300 s, whereas
somatodendritic labeling by this compound was
observed in a subset of neurons (arrowheads in
G and H).
(I) Fluorescence image of WT spinal cord at
300 s after PBB3 injection demonstrates no overt
retention of the tracer in the tissue.
(J and K) Ex vivo microscopy for a brain stem
section of the same Tg mouse. Tissues were
obtained at 60 min after PBB3 injection. Signals of
intravenously administered PBB3 (J) overlapped
with AT8 immunoreactivity (K).
Scale bars, 50 mm (A–F), 25 mm (G–I), and 25 mm
(J and K).
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Imaging of Tau Pathology in Model Mice and Humans60 min in WT mice (right panel in Figure 6E). The mean ratio at
45–90 min was increased by 40% in 12-month-old PS19 mice
as compared with age-matched WT mice (p < 0.01 by t test).
The agreement between localizations of PET signals and tau in-
clusions in PS19 mice was proven by postmortem FSB staining
of brain sections from scanned mice (Figure 6D). Significantly,
the mean target-to-reference ratio in the brain stem quantified
by PET correlated closely with the number of FSB-positive inclu-
sions per brain section in the same region of the postmortem
sample (p < 0.001 by t test; data not shown). [11C]PBB2 exhibited
slower clearance from the brain and higher nonspecific retention
in myelin-rich regions than [11C]PBB3 (Figure S6G), resulting in
insufficient contrast of tau-bound tracers in the brain stem of
PS19 mice and a small difference in the target-to-reference ratio
of radioactivities between PS19 and WT mice (8% at 45–90 min;
p < 0.05 by t test; Figure S6H) relative to those achieved with
[11C]PBB3.
As radiolabeling at the dimethylamino group in PBB5 with 11C
was unsuccessful, 11C-methylation of a hydroxyl derivative of
this compound was performed, leading to the production1100 Neuron 79, 1094–1108, September 18, 2013 ª2013 Elsevier Inc.of [11C]methoxy-PBB5 ([11C]mPBB5;
Figure S5C). PET images demon-
strated complex pharmacokinetics of
[11C]mPBB5 (Figures S5D and S5E), and
the difference in the specific radioligand
binding between Tg and WT mice was
small relative to the [11C]PBB3-PET data
(Figure S5F). After taking all of these find-
ings into consideration, [11C]PBB3 was
selected as the most suitable ligand forin vivo PET imaging of tau pathology in tau Tg mice and human
subjects.
Notably, the hippocampus of many PS19 mice was devoid of
overt [11C]PBB3 retention (Figure 6C), although a pronounced
hippocampal atrophy was noted in these animals. This finding
is in agreement with the well-known neuropathological features
of PS19 mice in the hippocampus, because the accumulation of
AT8-positive phosphorylated tau inclusions results in the degen-
eration of the affected hippocampal neurons prior to or immedi-
ately after NFT formation, followed by the clearance of their
preNFTs or NFTs that are externalized into the interstitial CNS
compartment (Figure S2). To explore the feasibility of our imaging
agents in studies with other tauopathy model mice, we also per-
formed fluorescence labelingwith PBBs for brain sections gener-
ated from rTg4510mice (Santacruz et al., 2005; theSupplemental
Experimental Procedures). As reported elsewhere (Santacruz
et al., 2005), these mice developed numerous thioflavin-S-posi-
tive neuronal tau inclusions in the neocortex and hippocampus,
and reactivity of these lesions with PBBs was demonstrated by
in vitro and ex vivo fluorescence imaging (Figure S7).
Figure 6. PET and Autoradiographic Detection of Tau Pathologies in PS19 Mice Using [11C]PBB2 and [11C]PBB3
(A) In vitro autoradiograms of PS19 and non-Tg WT hindbrains (coronal sections) and AD frontal cortex. Fibrillar aggregates in the mouse brain stem and AD
gray matter produced intense radiolabeling with both tracers, but nonspecific background signals were also observed at a considerably high level with the use of
[11C]PBB2. Binding of [11C]PBB3 was profoundly abolished by the addition of nonradioactive PBB3 (10 mM).
(B) Autoradiographic labeling with intravenously injected [11C]PBB2 and [11C]PBB3 in PS19 (Tg) and WT mice. The brains were removed at 45 min after injection
and were cut into sagittal slices. The autoradiographic section of PS19 brain was also stained with FSB. Arrows indicate the brain stem containing numerous tau
inclusions displayed at intermediate and high magnifications.
(C) Sagittal and coronal PET images generated by averaging dynamic scan data at 60–90 min after intravenous administration of [11C]PBB3. The images are
overlaid on theMRI template (images of the template alone are presented at the bottom). Arrows and asterisks indicate the brain stem and striatum, respectively,
and arrowhead denotes intense radiolabeling in the medial brain stem of the PS19 mouse.
(D) FSB staining of PS19 mouse brain shown in (C). Sagittal (left) and coronal (middle) images and a high-power view of fibrillar inclusions (right) are displayed.
Corresponding to high-level retention of [11C]PBB3 in PET scans, abundant FSB-positive lesions were found in the medial brain stem (arrow and arrowhead).
(E) Time-radioactivity curves (left) in the striatum (ST) and brain stem (BS) and BS-to-ST ratio of radioactivity (right) over the imaging time in PS19 (Tg; red symbols)
and WT (black symbols) mice (n = 5 each). Vertical bars in the graphs denote SEs.
Scale bars, 1 cm (A and B, top, middle, and bottom left panels); 1 cm (C and D, left and middle panels); 100 mm (B, bottom middle panel); and 100 mm (B, bottom
right panel and D, right panel). See also Figures S5, S6, and S7.
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Patients by Comparative PET Imaging with [11C]PBB3
and [11C]PIB
In order to compare the bindings of [11C]PBB3 and [11C]PIB to
tau-rich regions in the human brain, in vitro autoradiography
was carried out with sections of AD and control hippocampus.
A notable difference in labeling between these two radioligandsNeuwas observed in the CA1 sector and subiculum of the AD hippo-
campus, where fibrillar tau aggregates predominantly localized
to NFTs and neuropil threads (Figure 7A).
We subsequently conducted an exploratory clinical PET study
for patients with probable AD (n = 3) and age-matched cogni-
tively normal control (NC) subjects (n = 3). All AD patients
exhibited a marked increase in the retention of [11C]PIB inron 79, 1094–1108, September 18, 2013 ª2013 Elsevier Inc. 1101
Figure 7. Accumulation of [11C]PBB3 in the Hippocampal Formation
of AD Patients Revealed by In Vitro Autoradiography and In Vivo PET
(A) Autoradiographic labeling of adjacent brain sections from an AD patient
with 10 nM of [11C]PBB3 (left) and [11C]PIB (middle). The slices contain the
hippocampus (Hi), parahippocampal gyrus (PH), fusiform gyrus (FF), and white
matter (asterisks). Total binding (top) of [11C]PBB3 and [11C]PIB was markedly
abolished (bottom) by addition of nonradioactive PBB5 (100 mM) and thio-
flavin-S (10 mM), respectively, except for the nonspecific (NS) labeling of white
matter with [11C]PIB. The hippocampal CA1 sector and subiculum displayed
intense [11C]PBB3 signals without noticeable binding of [11C]PIB, and binding
of [11C]PBB3 in cortical areas flanking the collateral sulcus (identified by a red
dot) and hippocampal CA2 sector (arrows) was also abundant relative to that
of [11C]PIB. FSB staining of amyloid fibrils in the sections used for autoradi-
ography indicated the predominance of NFTs and diffuse plaques in the hip-
pocampal subiculum (Sub) and fusiform gyrus (FF), respectively (right panels),
supporting the strong reactivity of [11C]PBB3 with AD NFTs.
(B) MRI (left) and PET imaging with [11C]PBB3 (middle) and [11C]PIB (right)
performed in the same AD (top) and normal control (NC; bottom) subjects.
Coronal images containing the hippocampal formation (arrowheads) are dis-
played. [11C]PBB3- and [11C]PIB-PET images were generated by estimating
SUVRs at 30–70 min and 50–70 min after radiotracer injection, respectively,
and were superimposed on individual MRI data. In the hippocampal formation,
prominently increased retention of [11C]PBB3 in the AD patient was in sharp
contrast to the modest or negligible changes in [11C]PIB binding as compared
with NC. Scale ranges for SUVRs were 0.75–1.50 ([11C]PBB3) and 0.75–3.00
([11C]PIB).
See also Figure S9.
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These subjects then received a [11C]PBB3-PET scan, and the
[11C]PIB and [11C]PBB3 images were compared in the same in-
dividuals. Intravenously injected [11C]PBB3 was delivered to the
brain tissue despite its relatively rapid metabolism in humans1102 Neuron 79, 1094–1108, September 18, 2013 ª2013 Elsevier Inc(Figures 9A and 9B). Unlike [11C]PIB, [11C]PBB3 showedminimal
nonspecific binding to white matter and other anatomical struc-
tures with high myelin content, although it accumulated in dural
venous sinuses in control and AD brains (Figures 7B, 8, and 9B).
Time courses of regional radioactivity (Figures 9C and 9D; Fig-
ures S8A and S8B) and the standardized uptake value ratio
(SUVR) to the cerebellum (Figures S8C and S8D) demonstrated
accumulation of [11C]PBB3 in several brain regions of AD
patients as compared to controls (definition of these VOIs is indi-
cated in Figure S8E). In agreement with autoradiographic find-
ings, binding of [11C]PBB3 to the medial temporal region,
including the hippocampus, contrasted strikingly with the low-
level retention of [11C]PIB in this area (Figure 7B). There was a
slight increase in the retention of [11C]PBB3 primarily in the
medial temporal region of a control subject with a loss of several
points in Mini-Mental State Examination (MMSE) (subject 3 in
Figure 8), appearing similar to the tau pathology at Braak stage
III/IV or earlier (Braak and Braak, 1991), distinct from the lack
of enhanced [11C]PIB signals. Indeed, mild increase of medial
temporal SUVR (Figure 9E) contrasted with unremarkable
change in lateral temporal and frontal SUVRs in this subject (Fig-
ures 9G and 9H). Signals of [11C]PBB3 were also intense mainly
in the limbic region of a subject with early AD (subject 4 in Fig-
ure 8), but profound and moderate increases of SUVRs were
also observed in the lateral temporal and frontal cortices,
respectively, of this case (Figures 9G and 9H), resembling the
localization of tau deposits at Braak stage V/VI (Braak andBraak,
1991). With the further cognitive decline as scored by MMSE
(subjects 5 and 6 in Figure 8), additional increase in the retention
of [11C]PBB3 was found in the medial temporal region, precu-
neus, and frontal cortex (Figures 9E, 9F, and 9H). Meanwhile, a
substantial decline of [11C]PBB3 binding was noted in the lateral
temporal cortex of subject 6 (Figures 8 and 9G). The SUVRs in
the medial temporal region, precuneus, and frontal cortex were
consequently well correlated with the decline of MMSE scores
(Figures 9E, 9F, and 9H). In distinction with [11C]PBB3-PET
data, there was no overt association between the binding of
[11C]PIB and disease severity in AD patients (Figure 8), consis-
tent with previous observations. These data support the
potential utility of [11C]PBB3 for clarifying correlations between
the distribution of tau deposition and the symptomatic progres-
sion of AD.
As in vitro fluorescence staining indicated that PBB3 was
reactive with not only tau lesions but also several types of senile
plaques, particularly dense core plaques, density of binding
sites, and affinity of [11C]PBB3 for these sites were quantified
by autoradiographic binding assays with hippocampal and
neocortical sections of AD brains enriched with NFTs and senile
plaques, respectively. These analyses demonstrated that spe-
cific radioligand binding sites were primarily constituted by
high-affinity, low-capacity binding components in NFT-rich
regions and low-affinity, high-capacity binding components in
plaque-rich regions (Figures S9A and S9B). A subsequent
simulation for radioligand binding in an area containing these
two types of binding sites at a ratio of 1:1 indicated that the
selectivity of [11C]PBB3 for NFTs versus plaques may be
inversely associated with concentration of free radioligands (Fig-
ure S9C). In a range of free concentration in the brain achievable.
Figure 8. Orthogonal [11C]PBB3-PET Images in All Human Subjects Examined in the Present Exploratory Clinical Study
Data are displayed as parametric maps for SUVR. The [11C]PBB3 binding to the hippocampal formation (arrowheads) was increased consistently in AD patients in
contrast tominimum radiotracer retention in normal control (NC) subjects withMMSE scores of 29–30 points (subjects 1 and 2). Another NC subject with anMMSE
score of 27 points (subject 3) was negative for [11C]PIB-PETbut exhibited slight accumulation of radiotracer signals primarily around the hippocampus, resembling
fibrillar tau deposition at Braak stage III/IV or earlier. Sagittal slices around themidline illustrate that radioligand signals were the most intense in the limbic system
but began to expand to the neocortex in a patient with the mildest AD (subject 4), in agreement with the tau pathology at Braak stage V/VI, and was further
intensified inmost neocortical areas, corresponding to Braak stage VI, apparently as a function of the disease severity assessed byMMSE (subjects 5 and 6). The
AD patient with the lowest MMSE score (subject 6) displayed a less profound increase of [11C]PBB3 retention in the lateral temporal and parietal cortices than did
the other two AD cases, and this is attributable to marked cortical atrophy in this individual and/or toxic loss of tau-bearing neurons in these brain areas at an
advanced pathological stage. In contrast to the spatial profiles of [11C]PBB3 binding, the distribution of [11C]PIB signals appeared unchanged among AD subjects.
See also Figure S9.
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Figure 9. Pharmacokinetic Profiles of
[11C]PBB3 Administered to Humans and
PET Images of a Patient Clinically Diag-
nosed as Having Corticobasal Syndrome
(A) Time course of unmetabolized [11C]PBB3
fraction in plasma following intravenous radio-
tracer injection. The plot was generated by aver-
aging data from six individuals.
(B) Time-radioactivity curves in different brain re-
gions of cognitively normal control subjects over
70 min after intravenous injection of [11C]PBB3.
Data were generated by averaging values in two
individuals and are presented as standard uptake
values (SUVs).
(C and D) Comparisons of time-radioactivity
curves in the medial temporal region (C) and pre-
cuneus (D) of normal controls (black symbols and
lines; n = 3) and AD patients (red symbols and
lines; n = 3).
(E–H) Scatterplots illustrating correlation of SUVRs
with MMSE scores in the medial temporal region
(E), precuneus (F), and lateral temporal (G) and
frontal (H) cortices. Numbers beside symbols
denote subject ID as indicated in Figure 8.
Coefficients of determination (r2) and p values by
t test are displayed in graphs.
(I) [11C]PBB3- and [11C]PIB-PET images in a sub-
ject with clinical diagnosis of corticobasal syn-
drome. Images were generated as in Figures 7
and 8. Accumulation of [11C]PBB3 was noticeable
in the basal ganglia (red arrowheads) with right-
side dominance and an area containing the thal-
amus and midbrain (yellow arrowhead).
Vertical bars in the graphs represent SEs. See also
Figures S8 and S9.
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Imaging of Tau Pathology in Model Mice and Humansat a pseudoequilibrium state in human PET imaging (<0.2 nM),
[11C]PBB3 is presumed to preferentially bind to tau lesions rela-
tive to in vitro autoradiographic (1 nM) and fluorescence
(>100 nM) labeling.
We also estimated contribution of [11C]PBB3 bound to
dense core plaques to total radiosignals in the neocortical1104 Neuron 79, 1094–1108, September 18, 2013 ª2013 Elsevier Inc.gray matter of AD patients, by con-
ducting autoradiography and FSB
histochemistry for the same sections.
Radiolabeling associated with dense
cored plaques accounted for less than
1% and 3% of total gray matter signals
in the temporal cortex and precuneus,
respectively (Figures S9D–S9H). More-
over, fluorescence labeling of adjacent
sections with PBB3 demonstrated that
approximately 2% and 5% of total gray
matter fluorescence signals were attrib-
utable to PBB3 bound to dense core
plaques in the temporal cortex and pre-
cuneus, respectively. Hence, dense
cored plaques were conceived to be
rather minor sources of binding sites for
[11C]PBB3.Finally, PET scans with [11C]PBB3 and [11C]PIB were con-
ducted for a subject clinically diagnosed as having corticobasal
syndrome. Retention of [11C]PIB stayed at a control level,
but notable accumulation of [11C]PBB3 was observed in the
neocortex and subcortical structures (Figure 9I), providing evi-
dence for in vivo detection of tau lesions in plaque-negative
Neuron
Imaging of Tau Pathology in Model Mice and Humanstauopathies. Interestingly, right-side dominant [11C]PBB3-PET
signals in the basal ganglia were consistent with laterality of
atrophy in this area (Figure S8F). These findings may also be
associatedwith a right-side dominant decrease in cerebral blood
flow and left-side dominant motor signs in this patient.
DISCUSSION
Here, we report our efforts to develop BBB-penetrant ligands
that are capable of binding to and visualizing intracellular tau
aggregates in AD and non-AD tauopathies. These compounds
may accordingly be useful for the differential diagnosis of neuro-
logical conditions in elderly subjects on the basis of the distribu-
tion of tau lesions, thereby opening up novel avenues for
research in elucidating mechanisms of tau-mediated neurode-
generation, as well as tau-focused biomarkers and therapies.
Despite numerous efforts to develop imaging ligands to visu-
alize tau pathologies in the brains of patients with AD and related
tauopathies, the urgent need for these tau biomarkers remains
largely unmet. To address this significant challenge, we also
took advantage of a multimodal imaging system, which facili-
tates a quick and label-free validation of candidate compounds
in terms of their transfer to the brain and retention in tau-rich re-
gions. In addition, subcellular-resolution imaging optics exempli-
fied by two-photon laser scanning microscopy provided proof of
the rapid transfer of intravenously administered potential tau
pathology imaging agents from plasma to the CNS extracellular
matrix and subsequently to the cytoplasm of neurons, where
they can bind to intracellular tau inclusions. Based on these
encouraging preliminary data using nonlabeled compounds, a
subset of these compounds was radiolabeled for use in PET
imaging of Tg mice that model tau pathology, and a radioligand
that yielded the best visualization of tau lesions in these Tg mice
was selected for further testing in human AD patients and NC
subjects as well as patients with probable CBD. This stepwise
strategy enabled us to identify and advance the most promising
PET probe for the visualization and quantitative assessment of
tau pathology in the CNS of living human subjects. Interestingly,
another research group has recently reported development of
18F-labeled PET ligands for tau lesions mostly through assess-
ments of binding to brain tissues, but not recombinant tau
assemblies (Zhang et al., 2012; Chien et al., 2013), as in the pre-
sent approach. These radioligands have been implied to pro-
duce considerably high contrasts for tau pathologies in living
AD brains, and relatively long radioactive half-life of 18F would
enable delivery of radioligands from a radiosynthesis sites to
multiple PET facilities. [11C]PBB3 has distinct advantages over
these compounds, as exemplified by affinity for diverse tau
lesions, including Tg mouse tau aggregates, applicability to
multimodal imaging, and induction of smaller radioactive expo-
sure than 18F-labeled ligands.
In the present work, we clinically validated the performance of
[11C]PBB3 as a tau imaging agent by comparing the distribution
of [11C]PBB3 with that of [11C]PIB in AD brains. Tau deposits in
patients with moderate or severe AD are thought to be distrib-
uted extensively in the neocortical and limbic regions (classified
as Braak stage V/VI) (Braak and Braak, 1991), thereby resem-
bling localization of senile plaques, except for the predominanceNeuof tau aggregates in the hippocampal formation. This rationalizes
the use of radioactivity in themedial temporal area as an index to
validate an imaging probe for tau pathology versus Ab deposits
in AD patients from prodromal to advanced stages. Furthermore,
our preliminary data suggest that [11C]PBB3 may be capable of
capturing the temporospatial spreading of neurofibrillary tau
pathologies from the limbic system (Braak stage III/IV or earlier)
to neocortical areas (Braak stage V/VI) with the progression of
AD (Figure 8). A considerable subset of tau lesions at Braak stage
I/II is composed of phosphorylated tau deposits barely reactive
with thioflavin-S (i.e., pretangles), and NFTs are relatively low in
number and are confined to the transentorhinal cortex (Braak
and Braak, 1991; Braak et al., 2011). Therefore, detection of
these early tau pathologies would be more difficult. Our next-
stage clinical study with expanded sample size and wider range
of MMSE scores is currently ongoing to pursue tau accumulation
in normal controls and subjects with mild cognitive impairments
and AD at diverse stages and will bring more compelling insights
into the significance of tau PET imaging in early diagnosis and
prediction of AD. In addition, alterations of [11C]PBB3 retention
were indicated in the transition from mild to moderate AD.
Loss of PET signals in the lateral temporal cortex of a patient
with moderate AD (subject 6 in Figure 8) might not result from
atrophy of this region, as the hippocampus of the same subject
exhibited strong [11C]PBB3 binding despite marked atrophy.
Possible explanations for this change include formation of extra-
cellular NFTs and their envelopment by astrocytes in the degen-
erating neocortex, profoundly modifying accessibility of these
NFTs to exogenous molecules (Schmidt et al., 1988). This notion
would need to be examined by combined autoradiogarphic and
immunohistochemical assays of different brain regions.
Being able to visualize tau deposits with [11C]PBB3 in non-AD
tauopathies, such as PSP, CBD, and related disorders, is also of
major importance, as suggested in the present PET data the
support detectability of tau deposition in living CBD brains. As
compared with NFTs and neuropil threads in AD, abundant tau
deposits are largely confined to specific neuroanatomical loca-
tions of the CNS in tau-positive, plaque-negative illnesses, as
exemplified by PSP and CBD (Dickson et al., 2011), but the
homogenous and low-level background signals of [11C]PBB3
in brain parenchyma indicate the possibility of detecting tau
lesions in these disorders. Following such in vivo assessments,
a postmortem neuropathological evaluation of scanned subjects
would be required as a reference standard for PET assays of
non-AD tau pathologies.
[11C]PIB-positive plaque formation nearly plateaus prior to the
progression of brain atrophy in AD (Engler et al., 2006), but tau
abnormalities may bridge the chasm between Ab fibrillogenesis
and neuronal death. Consistent with this notion, our PET/MRI
data indicate that the deposition of tau inclusions as visualized
by the intense [11C]PBB3 labeling but lacking overt [11C]PIB
binding is closely associated with a local volume reduction in
the hippocampal formation. Indeed, our pilot clinical PET study
demonstrated that localized accumulation of [11C]PBB3 in the
medial temporal region of AD patients was accompanied by
marked hippocampal atrophy (Figure 7B). Notably, [11C]PBB3-
PET signals were substantially increased, notwithstanding the
atrophy-related partial volume effects on PET images, and thisron 79, 1094–1108, September 18, 2013 ª2013 Elsevier Inc. 1105
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neuronal death in AD. However, these data do not immediately
imply neurotoxicities of [11C]PBB3-reactive tau fibrils, in light of
MRI-detectable neurodegeneration uncoupled with [11C]PBB3
retention in the hippocampus of PS19 mice. In the hippocampal
formation of AD patients, neurons bearing NFTs that resemble
those in the PS19 hippocampus may drive neurodegeneration
similar to that observed in either the PS19 hippocampus or brain
stem, and this issue could be addressed in future studies using
[11C]PBB3-PET and MRI in diverse mouse models, including
PS19 and rTg4510 mice, and human subjects.
Our analyses of multiple b sheet ligands illustrated electro-
chemical and/or conformational diversities of b-pleated sheets
among amyloid aggregates, producing a selectivity of these
compounds for a certain spectrum of fibrillar pathologies (Fig-
ures 1 and S1). Lipophilicities of the b sheet ligands could deter-
mine their reactivity with noncored plaques, as noted among the
PBBs studied here (Figure 1), although the molecular properties
underlying this variation are yet to be elucidated. Meanwhile, we
noted that all b sheet ligands tested in the present study were
reactive with dense core plaques regardless of their lipophilic-
ities. This may affect in vivo PET signals, particularly in AD brain
areas with abundant cored plaques, such as the precuneus.
However, our combined autoradiographic and histochemical
assessments indicated that [11C]PBB3 bound to dense core pla-
ques accounts for less than 10% of total specific radioligand
binding in these areas, and this percentage in fact includes bind-
ing to tau fibrils in plaque neurites in addition to Ab amyloid core.
A second possibility to account for the diversity of ligand reac-
tivity to tau lesions may arise from the packing distance between
two juxtaposed b sheets in tau filaments and is discussed in the
Supplemental Discussion.
Notably, selectivity of [11C]PBB3 for tau versus aggregates
may depend on free radioligand concentration in the brain.
Our autoradiographic binding assays suggested that affinity of
[11C]PBB3 for NFTs is 40- to 50-fold higher than senile plaques,
but binding components on tau fibrils may be more readily
saturated by this radioligand than those on Ab fibrils.
[11C]PBB3-PET data in humans indicated that uptake of this
radioligand into the brain is less than one-third of [11C]PIB
uptake and that free radioligand concentration in the brain at
a pseudoequilibrium state is approximately 0.2 nM or lower.
In this range of concentration, [11C]PBB3 could preferentially
interact with high-affinity binding components formed by tau
assemblies. An excessive amount of radioligand in the brain
would result in saturation of radioligand binding to tau lesions
and increased binding to low-affinity, high-capacity binding
components in Ab plaques, and such overload of free radioli-
gand is more likely in regions with less abundant tau pathol-
ogies. This could be even more critical in capturing early tau
pathologies that originate in the hippocampal formation and
may require technical improvements and methodological re-
finements, including high-resolution imaging, correction for
motions of subjects during scans, and robust definition of
VOIs on the atrophic hippocampus.
Although nonspecific [11C]PBB3-PET signals in control human
subjects were generally low, radioligand retention in dural
venous sinuses was noticeable in all scanned individuals.1106 Neuron 79, 1094–1108, September 18, 2013 ª2013 Elsevier IncPossible mechanisms that underlie this property are discussed
in the Supplemental Discussion.
The present work has also implied the potential utility of multi-
modal imaging systems for translational development of thera-
peutic agents that counteract tau fibrillogenesis. Optical imaging
with a near-infrared fluorescent probe, such as PBB5, could pro-
vide the least invasive technique to assess tau accumulation in
living mouse models. As demonstrated by our in vitro and
ex vivo fluorescence labeling, all PBBs share a similarity in terms
of their reactivity with tau aggregates. Hence, PBB5 optics may
be applicable to early screening of therapeutic agents that sup-
press tau deposition, and the data on abundance of tau lesions
obtained by this approach may be translatable to advanced
stages of assessments using [11C]PBB3-PET in animal models
and humans. By contrast, pharmacokinetic properties of PBB5
(Figure S5) were found to be distinct from those of electrically
neutral PBBs, including PBB2 and PBB3. These considerations
would be of importance in developing and using fluorescent
ligands applicable to optical and PET imaging.
To conclude, our class ofmultimodal imaging agents offers the
possibility of visual investigations of fibrillary tau pathologies at
subcellular, cellular, and regional levels. These assay systems
are potentially powerful tools for the longitudinal evaluation of
anti-tau treatments (Marx, 2007), as a single probe may facilitate
a seamless, bidirectional translation betweenpreclinical and clin-
ical insights.PET tracerswouldalso serveamore immediate ther-
apeuticpurposebyenabling theassessment of theeffectsof anti-
Ab and anti-tau therapies on tau pathologies in living AD patients.
EXPERIMENTAL PROCEDURES
Compounds and Reagents
PBB1 (Wako Pure Chemical Industries), PBB2 (ABX), PBB3 (Nard Institute),
PBB4 (ABX), mPBB5 (Nard Institute), desmethyl precursor of [11C]PBB2
(2-[4-(4-aminophenyl)buta-1,3-dienyl]benzothiazol-6-ol; Nard Institute), des-
methyl precursor of [11C]PBB3 protected with a silyl group (5-[4-(6-tert-butyl-
dimethylsilyloxy-benzothiazol-2-yl)buta-1,3-dienyl]pyridine-2-amine; Nard
Institute), desmethyl precursor of [11C]mPBB5 (2-[4-(4-dimethylaminophenyl)
buta-1,3-dienyl]-3-ethyl-6-hydroxybenzothiazol-3-ium; Nard Institute),
and 2-[8-(4-dimethylaminophenyl)octa-1,3,5,7-tetraenyl]-3-ethylbenzothia-
zol-3-ium (DM-POTEB; Nard Institute) were custom synthesized. Information
on other chemicals is provided in the Supplemental Experimental Procedures.
ClogP for each compound was calculated using ACD Chemsketch logP soft-
ware (Advanced Chemistry Development).
Animal Models
Tg mice heterozygous for human T34 (4-repeat tau isoform with 1 N-terminal
insert) with FTDP-17 P301S mutation driven by mouse prion protein promoter,
also referred to as PS19mice (Yoshiyama et al., 2007), were bred and kept on a
C57BL/6 background. All mice studied here were maintained and handled in
accordance with the National Research Council’s Guide for the Care and
Use of Laboratory Animals and our institutional guidelines. Protocols for the
present animal experiments were approved by the Animal Ethics Committees
of the National Institute of Radiological Sciences.
Postmortem Brain Tissues
Procedures for preparation of human andmouse brain sections are given in the
Supplemental Experimental Procedures.
In Vitro and Ex Vivo Fluorescence Microscopy
Six micrometer paraffin sections generated from patient brains and 20 mm
frozen sections of mouse brains were stained with 103% b sheet ligands.
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cence signals from these compounds were captured by nonlaser (BZ-9000;
Keyence Japan) and confocal laser scanning (FV-1000; Olympus) micro-
scopes. In the confocal imaging, excitation/emission wavelengths (nm) were
optimized for each compound as follows: 405/420-520 (PBB3, FSB, PIB,
BF-227, BF-158, FDDNP, thioflavin-S), 488/520-580 (PBB2, PBB4), 515/
530-630 (PBB1, curcumin), and 635/645-720 (PBB5, BF-189, DM-POTEB).
Subsequently, the tested samples and adjacent sections probed serially
with each ligand were autoclaved for antigen retrieval, immunostained with
the anti-tau monoclonal antibody AT8 that is specific for tau phosphorylated
at Ser 202 and Thr 205 (Endogen), as well as a polyclonal antibody against
AbN3(pE), and inspected using the microscopes noted above. For ex vivo
imaging, PS19 and non-Tg WT at 10–12 months of age were anesthetized
with 1.5% (v/v) isoflurane and were given 1 mg/kg PBB1-4, 0.1 mg/kg
PBB5, or 10 mg/kg FSB by syringe via tail vein. The animals were killed by
decapitation at 60 min after tracer administration. Brain and spinal cord
were harvested and cut into 10-mm-thick sections on a cryostat (HM560).
The sections were imaged using microscopes as in the in vitro assays and
were labeled with either FSB or AT8, followed by microscopic re-examination.
Ex Vivo and In Vivo Multiphoton Imaging
Experimental procedures are given in the Supplemental Experimental
Procedures.
In Vivo and Ex Vivo Pulsed Laser Scanning Imaging
Noninvasive scans of isoflurane-anesthetized non-Tg WT and tau Tg mice at
12 months of age were performed using a small animal-dedicated optical
imager (eXplore Optix; ART). Scan protocols are given in the Supplemental
Experimental Procedures.
Radiosynthesis of [11C]PBB2
Experimental procedures are given in the Supplemental Experimental
Procedures.
Radiosynthesis of [11C]PBB3
[11C]Methyl iodide was produced and transferred into 300 ml of dimethyl sulph-
oxide (DMSO) containing 1.5–2mg of tert-butyldimethylsilyl desmethyl precur-
sor and 10 mg of potassium hydroxide at room temperature. The reaction
mixture was heated to 125C and maintained for 5 min. After cooling the reac-
tion vessel, 5 mg of tetra-n-butylammonium fluoride hydrate in 600 ml of water
was added to the mixture to delete the protecting group, and then 500 ml of
HPLC solvent was added to the reaction vessel. The radioactive mixture
was transferred into a reservoir for HPLC purification (CAPCELL PAK C18 col-
umn, 10 3 250 mm; acetonitrile/50 mM ammonium formate = 4/6, 6 ml/min).
The fraction corresponding to [11C]PBB3 was collected in a flask containing
100 ml of 25% ascorbic acid solution and 75 ml of Tween 80 in 300 ml of ethanol
and was evaporated to dryness under a vacuum. The residue was dissolved in
10 ml of saline (pH 7.4) to obtain [11C]PBB3 (970–1,990 GBq at the end of
synthesis [EOS]) as an injectable solution. The final formulated product was
radiochemically pure (R95%) as detected by analytic HPLC (CAPCELL PAK
C18 column, 4.6 3 250 mm; acetonitrile/50 mM ammonium formate = 4/6,
2 ml/min). The specific activity of [11C]PBB3 at EOS was 37–121 GBq/mmol,
and [11C]PBB3 maintained its radioactive purity exceeding 90% over 3 hr after
formulation.
Radiosynthesis of [11C]mPBB5
Experimental procedures are given as Supplemental Experimental
Procedures.
Radiosynthesis of [11C]PIB
Radiolabeling of PIB was performed as described elsewhere (Maeda et al.,
2011). The specific activity of [11C]PIB at EOS was 50–110 GBq/mmol.
In Vitro and Ex Vivo Autoradiography
Experimental procedures are given in the Supplemental Experimental
Procedures.NeuIn Vivo PET Imaging of Mice
PET scans were performed using a microPET Focus 220 animal scanner
(Siemens Medical Solutions) immediately after intravenous injection of
[11C]PBB2 (28.3 ± 10.3 MBq), [11C]PBB3 (29.7 ± 9.3 MBq), or [11C]mPBB5
(32.8 ± 5.9 MBq). Detailed procedures are provided in the Supplemental
Experimental Procedures.
In Vivo PET Imaging of Humans
Three cognitively normal control subjects (64, 72, and 75 years of age; mean
age, 70.3 years) and three AD patients (64, 75 and 77 years of age; mean
age, 72 years) were recruited to the present work (Figure 8). Additional infor-
mation on these subjects is given in the Supplemental Experimental Proce-
dures. The current clinical study was approved by the Ethics and Radiation
Safety Committees of the National Institute of Radiological Sciences. Written
informed consent was obtained from the subjects or their family members.
PET assays were conducted with a Siemens ECAT EXACT HR+ scanner
(CTI PET Systems). Detailed PET scan protocols are provided in the Supple-
mental Experimental Procedures. A fraction of radioactivity corresponding to
unmetabolized [11C]PBB3 in plasma at 3, 10, 20, 30, and 60 min was deter-
mined by HPLC (Waters mBondapak C18 column, 7.8 3 300 mm; acetoni-
trile/ammonium formate mobile phase with gradient elution = 40/60, 52/48,
80/20, 80/20, 40/60, and 40/60 at 0, 6, 7, 8, 9, and 15 min, respectively; flow
rate, 6 ml/min) as described elsewhere (Suzuki et al., 1999). The radiotracer
injection and following scans and plasma assays were conducted in a dimly
lit condition to avoid photoracemization of the chemicals.
Individual MRI data were coregistered to the PET images using PMOD soft-
ware (PMOD Technologies). Volumes of interest (VOIs) were drawn on coregis-
tered MR images and were transferred to the PET images. Procedures of
image analyses are provided in the Supplemental Experimental Procedures.
We additionally carried out PET scans of a patient who was clinically diag-
nosed as having corticobasal syndrome, as described in the Supplemental
Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
nine figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.neuron.2013.07.037.
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